Latest news with #US5.1

AU Financial Review

Resmed beats forecasts as annual sleep device sales hit $8bn

Resmed has beaten full-year earnings and revenue forecasts on the back of strong global sales of its devices to treat sleep apnoea, shrugging off the threat of Donald Trump's trade tariffs and flagging a significant improvement in margins this year. California-based Resmed, which was founded in Sydney 35 years ago and is listed on the Nasdaq and the ASX, said net profit rose 37 per cent to $US1.4 billion ($2.2 billion) in the year to June 30, while revenue for the year increased 10 per cent to $US5.1 billion.